title: Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.
abstract: With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
authors.affiliation: Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands. w.vanweerden@erasmusmc.nl
authors.forename: W M
authors.initials: WM
authors.lastname: van Weerden
authors.forename: C
authors.initials: C
authors.lastname: Bangma
authors.forename: R
authors.initials: R
authors.lastname: de Wit
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000818:Animals; D045744:Cell Line, Tumor; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen